Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Garvey WT, Frias JP, Jastreboff AM, et al. The Lancet 2023;402:613-626.
What it found
Mean body weight change of -12.8% (10 mg) and -14.7% (15 mg) vs -3.2% with placebo; 79-83% lost at least 5% vs 32%. Side effects were mainly gastrointestinal and led to stopping treatment in under 5%.
Limitations
Weight loss was smaller than in people without diabetes (SURMOUNT-1). Lifestyle intervention in all groups.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.